Modality
siRNA
MOA
FXIai
Target
WRN
Pathway
PI3K/AKT
CKDPSPMCL
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ Jun 2031
Phase 2Current
NCT04057105
1,682 pts·CKD
2019-09→2031-06·Completed
NCT03434604
2,735 pts·PSP
2021-06→2026-11·Terminated
4,417 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-137mo awayPh2 Data· PSP
2031-06-025.2y awayPh2 Data· CKD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Complet…
P2
Termina…
Catalysts
Ph2 Data
2026-11-13 · 7mo away
PSP
Ph2 Data
2031-06-02 · 5.2y away
CKD
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04057105 | Phase 2 | CKD | Completed | 1682 | DAS28 |
| NCT03434604 | Phase 2 | PSP | Terminated | 2735 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |